TABLE 2.
Population characteristics
| Characteristic | Teriparatide cohort (n = 153 316) | Comparator cohort (n = 613 247) |
|---|---|---|
| Sex, n (%) | ||
| Male | 13 426 (8.8) | 53 699 (8.8) |
| Female | 139 890 (91.2) | 559 548 (91.2) |
| Age (years) on index date, mean (SD) | 76.9 (7.64) | 77.0 (7.85) |
| Length of look‐back period (months), mean (SD) | 38.2 (28.69) | 38.0 (27.65) |
| Patients from states with participating cancer registries, n (%) | 100 033 (65.2) | 400 119 (65.2) |
| Use of corticosteroid drugs before the index date, n (%) | 58 953 (38.5) | 186 924 (30.5) |
| Use of other osteoporosis drugs before the index date, n (%) | 92 632 (60.4) | 162 905 (26.6) |
| Medications by AHFS therapeutic class within the 4 months before the index date, n (%) | ||
| Antihistamine drugs | 6758 (4.4) | 26 353 (4.3) |
| Anti‐infective agents | 69 434 (45.3) | 280 925 (45.8) |
| Antineoplastic agents | 10 732 (7.0) | 29 034 (4.7) |
| Autonomic drugs | 47 648 (31.1) | 167 263 (27.3) |
| Blood derivatives | 0 (0.0) | n < 11 |
| Blood formation, coagulation, and thrombosis agents | 27 958 (18.2) | 122 156 (19.9) |
| Cardiovascular drugs | 112 092 (73.1) | 508 567 (82.9) |
| Central nervous system agents | 109 903 (71.7) | 392 259 (64.0) |
| Diagnostic agents | 139 (0.1) | 2210 (0.4) |
| Electrolytic, caloric, and water balance | 56 889 (37.1) | 303 711 (49.5) |
| Enzymes | 409 (0.3) | 2274 (0.4) |
| Respiratory tract agents | 8567 (5.6) | 28 263 (4.6) |
| Eye, ear, nose, and throat preparations | 38 452 (25.1) | 162 231 (26.5) |
| Gastrointestinal drugs | 74 206 (48.4) | 265 962 (43.4) |
| Gold compounds | 18 (0.0) | n < 11 |
| Heavy‐metal antagonists | 45 (0.0) | 59 (0.0) |
| Hormones and synthetic substitutes | 82 052 (53.5) | 336 900 (54.9) |
| Local anesthetics | 1302 (0.8) | 6094 (1.0) |
| Oxytocics | 0 (0.0) | 0 (0.0) |
| Serums, toxoids, and vaccines | 2209 (1.4) | 7113 (1.2) |
| Skin and mucous membrane agents | 40 572 (26.5) | 148 909 (24.3) |
| Smooth muscle relaxants | 12 621 (8.2) | 45 692 (7.5) |
| Vitamins | 3735 (2.4) | 9982 (1.6) |
| Miscellaneous therapeutic agents | 53 507 (34.9) | 132 440 (21.6) |
| Unclassified | 0 (0.0) | 0 (0.0) |
| Number of unique AHFS therapeutic classes within the 4 months before the index date, n (%) | ||
| 0‐2 | 14 442 (9.4) | 57 767 (9.4) |
| 3‐5 | 32 311 (21.1) | 129 244 (21.1) |
| 6‐8 | 37 512 (24.5) | 150 047 (24.5) |
| 9‐11 | 30 431 (19.8) | 121 722 (19.8) |
| 12‐15 | 24 141 (15.7) | 96 563 (15.7) |
| >15 | 14 479 (9.4) | 57 904 (9.4) |
Abbreviations: AHFS = American Hospital Formulary Services.
Note: To protect patient privacy, non‐zero cell counts <11 cannot be disclosed for Medicare data.